FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations

Disease Sites:

Miscellaneous

Staging:

Phase I

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Enfotumab Vedotin-EV, LOXO-435, Pembrolizumab

Principal Investigator(s):

Tan, Alan

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

12-23-2025

Trial Type:

Treatment

Protocol ID:

VICCURO24518

National Clinical Trial ID:

NCT05614739

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available